Intra-Cellular Therapies (NASDAQ:ITCI) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI) in a report released on Thursday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also commented on ITCI. Needham & Company LLC reiterated a “hold” rating and issued a $100.00 price objective on shares of Intra-Cellular Therapies in a research report on Monday, January 13th. Piper Sandler reiterated a “neutral” rating and issued a $132.00 price target (up from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. JPMorgan Chase & Co. lifted their price objective on Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an “overweight” rating in a research report on Monday, November 4th. Leerink Partnrs cut Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Finally, Morgan Stanley boosted their price target on Intra-Cellular Therapies from $92.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Eight investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $102.15.

Intra-Cellular Therapies Trading Down 0.1 %

Shares of Intra-Cellular Therapies stock opened at $127.07 on Thursday. The company has a 50-day moving average of $91.53 and a two-hundred day moving average of $82.02. Intra-Cellular Therapies has a 12-month low of $62.78 and a 12-month high of $128.00. The stock has a market cap of $13.47 billion, a PE ratio of -146.06 and a beta of 0.70.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The firm had revenue of $175.40 million during the quarter, compared to analysts’ expectations of $172.30 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business’s revenue for the quarter was up 39.0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.25) earnings per share. On average, sell-side analysts forecast that Intra-Cellular Therapies will post -0.64 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Sharon Mates sold 51,000 shares of the stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total value of $4,375,800.00. Following the transaction, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at approximately $91,834,228.20. This trade represents a 4.55 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, President Michael Halstead sold 22,869 shares of Intra-Cellular Therapies stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $89.12, for a total value of $2,038,085.28. The disclosure for this sale can be found here. Corporate insiders own 2.60% of the company’s stock.

Institutional Trading of Intra-Cellular Therapies

A number of institutional investors and hedge funds have recently bought and sold shares of the business. R Squared Ltd acquired a new position in Intra-Cellular Therapies during the fourth quarter valued at approximately $205,000. KBC Group NV raised its stake in shares of Intra-Cellular Therapies by 31.8% in the 4th quarter. KBC Group NV now owns 3,774 shares of the biopharmaceutical company’s stock valued at $315,000 after acquiring an additional 910 shares during the period. SG Americas Securities LLC lifted its holdings in shares of Intra-Cellular Therapies by 204.4% during the 4th quarter. SG Americas Securities LLC now owns 12,917 shares of the biopharmaceutical company’s stock valued at $1,079,000 after acquiring an additional 8,673 shares in the last quarter. Cetera Trust Company N.A boosted its position in Intra-Cellular Therapies by 17.3% during the 4th quarter. Cetera Trust Company N.A now owns 2,955 shares of the biopharmaceutical company’s stock worth $247,000 after purchasing an additional 435 shares during the period. Finally, Barlow Wealth Partners Inc. purchased a new stake in Intra-Cellular Therapies during the 4th quarter worth $184,000. Institutional investors and hedge funds own 92.33% of the company’s stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.